SPIN3: A Drug Target / Disease Biomarker (G169981)

Target Name: SPIN3

NCBI ID: G169981

SPIN3

SPIN3: A Drug Target / Disease Biomarker

SPIN3, short for Src-Protein Inhibitors of NEDD8-activated Kinases 3, is a drug target and a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique mechanism of action, as well as its potential to be a druggable target, has made it an attractive target for researchers in the pharmaceutical industry.

SPIN3 functions as a negative regulator of the NEDD8-activated kinases (NAKs), a family of enzymes that play a crucial role in various cellular processes, including cell signaling, DNA repair, and inflammation. NAKs have been implicated in the development and progression of numerous diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

SPIN3 is a protein that is expressed in various tissues and cells, including the brain, spinal cord, and peripheral tissues. It is composed of a unique transmembrane domain that is responsible for its unique mechanism of action. This transmembrane domain is known as the N-terminal hypervariable region (HVR) and is involved in the regulation of SPIN3's activity.

The NHR of SPIN3 is composed of a variable region and a constant region. The variable region is responsible for the regulation of SPIN3's activity, while the constant region provides the structural stability necessary for the protein to maintain its stability and function.

The NHR of SPIN3 is unique in that it contains a conserved region, known as the ATP-binding site, which is essential for the regulation of SPIN3's activity. This conserved region is located in the NHR and is responsible for the regulation of SPIN3's ATP-dependent hydrolysis of the N-terminal domain.

SPIN3's unique mechanism of action is based on its ability to inhibit the activity of NAKs. NAKs are enzymes that regulate various cellular processes, including cell signaling, DNA repair, and inflammation. The activity of NAKs is dependent on the activity of the ATPase enzyme, which is responsible for the production of ATP.

SPIN3 inhibits the activity of NAKs by binding to the ATPase enzyme and preventing it from activating. This inhibition of NAK activity has been shown to have a variety of therapeutic potential.

SPIN3 has been shown to be a potential drug target for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, studies have shown that SPIN3 is overexpressed in various tissues and that its expression is associated with the development and progression of certain diseases.

In addition, SPIN3 has also been shown to be a potential biomarker for various diseases, including cancer. For example, studies have shown that SPIN3 is overexpressed in various cancer tissues and that its expression is associated with the progression of cancer.

The potential drug targets for SPIN3 are numerous. One of the most promising targets is the inhibition of SPIN3, which has been shown to have therapeutic potential in a variety of diseases. Another target is the inhibition of SPIN3's activity, which has been shown to have therapeutic potential in the treatment of various neurological and psychiatric disorders.

In conclusion, SPIN3 is a drug target and a potential biomarker for various diseases. Its unique mechanism of action, as well as its potential to be a druggable target, has made it an attractive target for researchers in the pharmaceutical industry. Further studies are needed to fully understand the potential therapeutic potential of SPIN3.

Protein Name: Spindlin Family Member 3

Functions: Exhibits H3K4me3-binding activity

The "SPIN3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SPIN3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets